Natixis
BCYC icon

Natixis’s Bicycle Therapeutics BCYC Stock Holding History

Natixis’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20K Hold
4,645
– – ﹤0.01% 1059
2026
Q1 		$21.2K Hold
4,645
– – ﹤0.01% 1007
2025
Q4 		$31.6K Buy
4,645
+2,698
+139% +$19.9K ﹤0.01% 1020
2025
Q3 		$14.6K Hold
1,947
– – ﹤0.01% 979
2025
Q2 		$13.9K Sell
1,947
-179
-8% -$1.43K ﹤0.01% 945
2025
Q1 		$17.9K Sell
2,126
-172
-7% -$2.03K ﹤0.01% 876
2024
Q4 		$33.2K Sell
2,298
-437
-16% -$9.37K ﹤0.01% 913
2024
Q3 		$62.8K Sell
2,735
-147
-5% -$3.39K ﹤0.01% 775
2024
Q2 		$57.9K Buy
2,882
+314
+12% +$7.09K ﹤0.01% 778
2024
Q1 		$63.2K Sell
2,568
-61
-2% -$1.3K ﹤0.01% 811
2023
Q4 		$47.6K Sell
2,629
-139
-5% -$2.3K ﹤0.01% 829
2023
Q3 		$55.1K Sell
2,768
-7
-0.3% -$160 ﹤0.01% 816
2023
Q2 		$69.9K Sell
2,775
-625
-18% -$14.5K ﹤0.01% 822
2023
Q1 		$73.7K Sell
3,400
-213
-6% -$5.34K ﹤0.01% 806
2022
Q4 		$107K Buy
+3,613
New +$96.9K ﹤0.01% 870

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Natixis's BCYC Position: Q2 2026 in Review

Natixis held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 4,645 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Natixis first reported a position in BCYC in Q4 2022 and has held it in 15 quarters since. The position peaked at $107K in Q4 2022. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Natixis held 4,645 shares of Bicycle Therapeutics worth $20K as of Q2 2026.
  • Natixis left its Bicycle Therapeutics share count unchanged in Q2 2026.
  • Bicycle Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #1059 holding.
  • Natixis first reported a position in Bicycle Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Natixis's Bicycle Therapeutics position peaked at $107K in Q4 2022.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.